ArticleEClinicalMedicine2024

Camrelizumab combined with apatinib and nanoparticle albumin-bound paclitaxel in lung adenocarcinoma (CAPAP-lung): a single-arm phase II study.

Xingxiang Pu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.